公开(公告)号：FI94414C

公开(公告)日：1995-09-11

申请号：FI875024

申请日：1987-11-13

Applicant: HOFFMANN LA ROCHE

Inventor： BRANCA QUIRICO ,  JAUNIN ROLAND ,  MAERKI HANS PETER ,  MARTI FRAENZI ,  RAMUZ HENRI

IPC: A61K31/415 ,  A61K31/4184 ,  A61K31/425 ,  A61K31/428 ,  A61K31/44 ,  A61K31/55 ,  A61K31/551 ,  A61P9/00 ,  A61P9/06 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  C07D233/54 ,  C07D233/64 ,  C07D235/14 ,  C07D235/26 ,  C07D243/14 ,  C07D277/62 ,  C07D277/64 ,  C07D401/06 ,  C07D471/04 ,  C07D487/04 ,  C07D521/00 ,  C07D235/04

公开(公告)号：FI94414B

公开(公告)日：1995-05-31

申请号：FI875024

申请日：1987-11-13

Applicant: HOFFMANN LA ROCHE

Inventor： BRANCA QUIRICO ,  JAUNIN ROLAND ,  MAERKI HANS PETER ,  MARTI FRAENZI ,  RAMUZ HENRI

IPC: A61K31/415 ,  A61K31/4184 ,  A61K31/425 ,  A61K31/428 ,  A61K31/44 ,  A61K31/55 ,  A61K31/551 ,  A61P9/00 ,  A61P9/06 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  C07D233/54 ,  C07D233/64 ,  C07D235/14 ,  C07D235/26 ,  C07D243/14 ,  C07D277/62 ,  C07D277/64 ,  C07D401/06 ,  C07D471/04 ,  C07D487/04 ,  C07D521/00 ,  C07D235/04

Abstract: Compounds of the formula I wherein R is lower-alkyl, R1 is halogen, R2 is C1-C12-alkyl, R3 is hydroxy, lower-alkoxy, lower-alkyl-carbonyloxy, lower-alkoxy-lower-alkylcarbonoyloxy, lower-alkylaminocarbonyloxy, arylaminocarbonyloxy or aryl-lower alkylaminocarbonyloxy, X is C1-C18-alkylene which optionally can be interrupted by 1,4-phenylene or interrupted or lengthened by 1,4-cyclohexylene, A is di- or tri-substituted 2-imidazolyl attached via an ethylene group or a substituted or unsubstituted heterocycle selected from the group consisting of benzimidazolyl, benzimidazolonyl, imidazo[4,5-c]pyridinyl, imidazo[4,5-c]pyridinonyl, benzthiazolyl, benzodiazepine-2,5-dion-1-yl and pyrrolo[2,1-c]-[1,4]benzodiazepine-5,11-dion-10-yl and n is the number 0 or 1, in the form of racemates and optical antipodes, as well as N-oxides and pharmaceutically usable acid addition salts thereof. The compounds of formual I have a pronounced calcium-antagonistic and anti-arrhythmic activity and can accordingly be used as medicaments, especially for the control or prevention of angina pectoris, ischaemia, arrhythmias, high blood pressure and cardiac insufficiency.

公开(公告)号：SG114194G

公开(公告)日：1994-11-25

申请号：SG114194

申请日：1994-08-13

Applicant: HOFFMANN LA ROCHE

Inventor： BRANCA QUIRICO ,  JAUNIN ROLAND ,  MAERKI HANS P ,  MARTI FRAENZI ,  RAMUZ HENRI

IPC: A61K31/415 ,  A61K31/4184 ,  A61K31/425 ,  A61K31/428 ,  A61K31/44 ,  A61K31/55 ,  A61K31/551 ,  A61P9/00 ,  A61P9/06 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  C07D233/54 ,  C07D233/64 ,  C07D235/14 ,  C07D235/26 ,  C07D243/14 ,  C07D277/62 ,  C07D277/64 ,  C07D401/06 ,  C07D471/04 ,  C07D487/04 ,  C07D521/00

Abstract: Compounds of the formula I wherein R is lower-alkyl, R1 is halogen, R2 is C1-C12-alkyl, R3 is hydroxy, lower-alkoxy, lower-alkyl-carbonyloxy, lower-alkoxy-lower-alkylcarbonoyloxy, lower-alkylaminocarbonyloxy, arylaminocarbonyloxy or aryl-lower alkylaminocarbonyloxy, X is C1-C18-alkylene which optionally can be interrupted by 1,4-phenylene or interrupted or lengthened by 1,4-cyclohexylene, A is di- or tri-substituted 2-imidazolyl attached via an ethylene group or a substituted or unsubstituted heterocycle selected from the group consisting of benzimidazolyl, benzimidazolonyl, imidazo[4,5-c]pyridinyl, imidazo[4,5-c]pyridinonyl, benzthiazolyl, benzodiazepine-2,5-dion-1-yl and pyrrolo[2,1-c]-[1,4]benzodiazepine-5,11-dion-10-yl and n is the number 0 or 1, in the form of racemates and optical antipodes, as well as N-oxides and pharmaceutically usable acid addition salts thereof. The compounds of formual I have a pronounced calcium-antagonistic and anti-arrhythmic activity and can accordingly be used as medicaments, especially for the control or prevention of angina pectoris, ischaemia, arrhythmias, high blood pressure and cardiac insufficiency.

公开(公告)号：AU3995393A

公开(公告)日：1993-12-09

申请号：AU3995393

申请日：1993-06-01

Applicant: HOFFMANN LA ROCHE

Inventor： BRANCA QUIRICO ,  STADLER HEINZ ,  VIEIRA ERIC ,  WOSTL WOLFGANG

IPC: A61K31/415 ,  A61K31/44 ,  A61K31/4406 ,  A61K31/4418 ,  A61P9/00 ,  A61P9/12 ,  A61P43/00 ,  C07C317/44 ,  C07D213/56 ,  C07D233/54 ,  C07D233/64

公开(公告)号：ZA933795B

公开(公告)日：1993-12-06

申请号：ZA933795

申请日：1993-05-28

Applicant: HOFFMANN LA ROCHE

Inventor： BRANCA QUIRICO ,  STADLER HEINZ ,  VIEIRA ERIC ,  WOSTL WOLFGANG

IPC: A61K31/415 ,  A61K31/44 ,  A61K31/4406 ,  A61K31/4418 ,  A61P9/00 ,  A61P9/12 ,  A61P43/00 ,  C07C317/44 ,  C07D213/56 ,  C07D233/54 ,  C07D233/64 ,  C07C ,  A61K

公开(公告)号：MX15142A

公开(公告)日：1993-11-01

申请号：MX1514289

申请日：1989-03-03

Applicant: HOFFMANN LA ROCHE

Inventor： BRANCA QUIRICO

IPC: A61K20060101 ,  C07C20060101 ,  C07D20060101 ,  C07D233/64 ,  C07K20060101

公开(公告)号：MX26375A

公开(公告)日：1993-09-01

申请号：MX2637591

申请日：1991-06-25

Applicant: HOFFMANN LA ROCHE

Inventor： BRANCA QUIRICO

IPC: A61K31/435 ,  A61K31/495 ,  A61K31/50 ,  A61P9/00 ,  A61P9/12 ,  C07D263/06 ,  C07D471/04 ,  C07D487/04 ,  C07D487/02

Abstract: The compounds of the formula in which A, B, X, Y, R , R , R , R and R have the meaning given in Claim 1, in the form of optically pure diastereomers, diastereomer mixtures, diastereomeric racemates or mixtures of diastereomeric racemates and pharmaceutically utilisable salts thereof inhibit the action of the natural enzyme renin and can therefore be used in the form of pharmaceutical preparations in the control or prevention of high blood pressure and cardiac insufficiency. They can be prepared by various processes known per se.

公开(公告)号：HUT62864A

公开(公告)日：1993-06-28

申请号：HU9201224

申请日：1992-04-10

Applicant: HOFFMANN LA ROCHE

Inventor： BRANCA QUIRICO ,  HEINTZ MARIE-PAULE ,  NEIDHART WERNER ,  STADLER HEINZ ,  VIEIRA ERIC ,  WOSTL WOLFGANG

IPC: A61K31/16 ,  A61K31/165 ,  A61K31/215 ,  A61K31/22 ,  A61K31/415 ,  A61K31/425 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4418 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/535 ,  A61P9/00 ,  A61P9/04 ,  A61P9/12 ,  C07C317/44 ,  C07C317/50 ,  C07C323/51 ,  C07D207/08 ,  C07D207/12 ,  C07D211/22 ,  C07D213/40 ,  C07D213/53 ,  C07D213/56 ,  C07D231/12 ,  C07D233/54 ,  C07D233/56 ,  C07D233/58 ,  C07D233/60 ,  C07D233/61 ,  C07D233/64 ,  C07D277/20 ,  C07D277/30 ,  C07D295/088 ,  C07D295/185 ,  C07D295/205 ,  C07D307/54 ,  C07D317/24 ,  C07D333/24 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D521/00 ,  C07H15/12 ,  C07D233/24 ,  C07D407/12

Abstract: The compounds of the formula in which A, R , R , R , R and R have the meaning given in Claim 1, in the form of optically pure diastereomers, diastereomer mixtures, diastereomeric racemates or mixtures of diastereomeric racemates and pharmaceutically utilisable salts thereof inhibit the action of the natural enzyme renin and can accordingly be used in the form of pharmaceutical preparations in the control or prevention of high blood pressure and cardiac insufficiency. They can be prepared by various processes known per se.

公开(公告)号：NZ232695A

公开(公告)日：1993-02-25

申请号：NZ23269590

申请日：1990-02-27

Applicant: HOFFMANN LA ROCHE

Inventor： BRANCA QUIRICO ,  EDENHOFER ALBRECHT ,  MARTIN JOSEPH ARMSTRONG ,  MERRETT JOHN HERBERT ,  NEIDHART WERNER

IPC: A61K31/195 ,  A61K31/27 ,  A61K31/335 ,  A61K31/357 ,  A61K31/42 ,  A61K31/421 ,  A61K31/47 ,  A61K31/472 ,  A61K38/00 ,  A61P31/12 ,  C07C211/08 ,  C07C211/36 ,  C07C229/30 ,  C07C233/88 ,  C07C237/22 ,  C07C251/36 ,  C07C271/22 ,  C07D213/40 ,  C07D217/06 ,  C07D233/26 ,  C07D263/04 ,  C07D295/12 ,  C07D295/13 ,  C07D295/20 ,  C07D295/205 ,  C07D317/30 ,  C07D405/12 ,  C07D413/12 ,  C07F7/18 ,  C07K1/113 ,  C07K5/02 ,  C07K5/06 ,  A61K31/16 ,  A61K31/415 ,  A61K31/495 ,  A61K31/535 ,  A61K31/54 ,  A61K37/02 ,  A61K37/64 ,  C07D217/16 ,  C07D233/64

公开(公告)号：AU1478892A

公开(公告)日：1992-10-22

申请号：AU1478892

申请日：1992-04-09

Applicant: HOFFMANN LA ROCHE

Inventor： BRANCA QUIRICO ,  HEITZ MARIE-PAULE ,  NEIDHART WERNER ,  STADLER HEINZ ,  VIEIRA ERIC ,  WOSTL WOLFGANG

IPC: A61K31/16 ,  A61K31/165 ,  A61K31/215 ,  A61K31/22 ,  A61K31/415 ,  A61K31/425 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4418 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/535 ,  A61P9/00 ,  A61P9/04 ,  A61P9/12 ,  C07C317/44 ,  C07C317/50 ,  C07C323/51 ,  C07D207/08 ,  C07D207/12 ,  C07D211/22 ,  C07D213/40 ,  C07D213/53 ,  C07D213/56 ,  C07D231/12 ,  C07D233/54 ,  C07D233/56 ,  C07D233/58 ,  C07D233/60 ,  C07D233/61 ,  C07D233/64 ,  C07D277/20 ,  C07D277/30 ,  C07D295/088 ,  C07D295/185 ,  C07D295/205 ,  C07D307/54 ,  C07D317/24 ,  C07D333/24 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D521/00 ,  C07H15/12 ,  C07K5/06 ,  A61K37/02

Abstract: The compounds of the formula in which A, R , R , R , R and R have the meaning given in Claim 1, in the form of optically pure diastereomers, diastereomer mixtures, diastereomeric racemates or mixtures of diastereomeric racemates and pharmaceutically utilisable salts thereof inhibit the action of the natural enzyme renin and can accordingly be used in the form of pharmaceutical preparations in the control or prevention of high blood pressure and cardiac insufficiency. They can be prepared by various processes known per se.